The EPSRC Future Manufacturing Research Hub for Continuous Manufacturing and Advanced Crystallisation (CMAC) was co-created with industry to address key manufacturing challenges and skills needs for the medicines manufacturing sector. CMAC comprises 7 leading UK Universities (Bath, Cambridge, Imperial, Loughborough, Leeds, Sheffield and Strathclyde), and 8 global Pharmaceutical partners (AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Pfizer, Roche and Takeda). CMAC’s vision is to deliver predictive design tools and novel integrated continuous processing platforms for the supply of next generation high performance personalised products. This vision will enable the pharmaceutical and chemical industries to deliver high quality products in a more economical, efficient and sustainable manner, by advanced continuous manufacturing.
CMAC’s world-class, bespoke PhD training programme combines dynamic, multi-disciplinary training with pioneering research projects. Our programme is aligned to the Hub research vision and our projects are informed by the needs of our industrial partners.
Our distinctive programme offers the following benefits to our PhD students:
Successful candidates will emerge with highly sought-after multidisciplinary skills and the skill-set necessary to address the future needs in the medicines manufacturing sector.
We are inviting applications for 3.5 and 4 year, fully funded studentships commencing October 2020 from students with a background in relevant disciplines of Science and Engineering, including Pharmaceutical Science, Chemistry, Chemical Engineering, Mechanical Engineering, Physics and other related disciplines. Applications are welcomed from UK/EU students with, or expecting to obtain, a first class or upper second class honours degree in relevant disciplines.
For more details on how to apply, or to find out more about the programme and opportunities, please visit the CMAC website or email [email protected]